Research Article| Volume 239, ISSUE 1, P67-74, December 15, 2005

Download started.


Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial


      The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif®), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex®), in reducing relapses and magnetic resonance imaging (MRI) activity in patients with relapsing–remitting multiple sclerosis at both 24 and 48 weeks of therapy. We now present final comparative data on these patients, showing that the superior efficacy of IFN beta-1a, 44mcg sc tiw, for relapse measures and MRI activity, compared with IFN beta-1a, 30mcg im qw, was sustained for at least 16 months. The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • PRISMS Study Group
        Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis.
        Lancet. 1998; 352: 1498-1504
        • PRISMS Study Group
        • University of British Columbia MS/MRI Analysis Group
        PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS.
        Neurology. 2001; 56: 1628-1636
        • Li D.K.B.
        • Paty D.W.
        • PRISMS Study Group
        Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing–remitting multiple sclerosis.
        Neurol. 1999; 46: 197-206
        • The IFNβ Multiple Sclerosis Study Group
        Interferon beta-1b is effective in relapsing–remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.
        Neurology. 1993; 43: 655-661
        • Durelli L.
        • Verdun E.
        • Barbero P.
        • Bergui M.
        • Versino E.
        • Ghezzi A.
        • et al.
        Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis. Results of a 2-year prospective randomised multicentre study (INCOMIN).
        Lancet. 2002; 359: 1453-1460
        • Rothuizen L.E.
        • Buclin T.
        • Spertinei F.
        • Trinchard I.
        • Munafo A.
        • Buchwalder P.A.
        • et al.
        Influence of interferon β-1a dose frequency of PBMC cytokine secretion and biological effect markers.
        J Neuroimmunol. 1999; 99: 131-141
        • Williams G.J.
        • Witt P.L.
        Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex.
        J Interferon Cytokine Res. 1998; 18: 967-975
        • Stürzebecher R.
        • Maibauer R.
        • Heuner A.
        • Beckman K.
        • Aufdembrinke B.
        Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers.
        J Interferon Cytokine Res. 1999; 19: 1257-1264
        • Antonetti F.
        • Finocchiaro O.
        • Mascia M.
        • Terlizzese M.G.
        • Jaber A.
        A comparison of the biologic activity of two recombinant IFN-β preparations used in the treatment of relapsing–remitting multiple sclerosis.
        J Interferon Cytokine Res. 2002; 22: 1181-1184
        • Panitch H.
        • Goodin D.S.
        • Francis G.
        • Chang P.
        • Coyle P.K.
        • O'Connor P.
        • et al.
        Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial.
        Neurology. 2002; 59: 1496-1506
        • Schwid S.R.
        • Thorpe J.
        • Sharief M.
        • Sandberg-Wollheim M.
        • Rammohan K.
        • Wendt J.
        • et al.
        Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study.
        Arch Neurol. 2005; 62: 785-792
        • Francis G.S.
        • Rice G.P.A.
        • Alsop J.C.
        • for the PRISMS Study Group
        Interferon beta-1a in MS; results following development of neutralizing antibodies in PRISMS.
        Neurology. 2005; 65: 48-55
        • Sandberg-Wollheim M.
        • Bever C.
        • Carter J.
        • Farkkila M.
        • Hurwitz B.
        • Lapierre Y.
        • et al.
        Comparative tolerance of IFN beta-1a regimens in patients with relapsing MS: EVIDENCE study.
        J Neurol. 2005; 252: 8-13
        • Francis G.S.
        • Grumser Y.
        • Alteri E.
        • Micaleff A.
        • O'Brien F.
        • Alsop J.
        • et al.
        Hepatic reactions during treatment of multiple sclerosis with interferon beta-1a. Incidence and clinical significance.
        Drug Safety. 2003; 26: 815-827
        • Gold R.
        • Rieckmann P.
        • Chang P.
        • Abdalla J.
        The long-term safety and tolerability of high-dose interferon beta-1a in relapsing–remitting multiple sclerosis: 4-year data from the PRISMS study.
        Eur J Neurol. 2005; 12: 649-656
        • Rieckmann P.
        • O'Connor P.
        • Francis G.S.
        • Wetherill G.
        • Alteri E.
        Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
        Drug Safety. 2004; 27: 745-756
        • Jacobs L.D.
        • Cookfair D.L.
        • Rudick R.A.
        • Herndon R.M.
        • Richert J.R.
        • Salazar A.M.
        • et al.
        Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.
        Ann Neurol. 1996; 39: 285-294
        • Schwid S.R.
        • Bever C.T.
        The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
        Neurology. 2001; 56: 1620